A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation

被引:1660
作者
Van Gelder, IC
Hagens, VE
Bosker, HA
Kingma, JH
Kamp, O
Kingma, T
Said, SA
Darmanata, JI
Timmermans, AJM
Tijssen, JGP
Crijns, HJGM
机构
[1] Univ Groningen Hosp, Thoraxctr, Dept Cardiol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen Hosp, Trial Coordinat Ctr, NL-9700 RB Groningen, Netherlands
[3] Rijnstate Hosp, Arnhem, Netherlands
[4] St Antonius Hosp, Nieuwegein, Netherlands
[5] Free Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[6] Hosp Midden Twente, Hengelo, Netherlands
[7] Twenteborg Hosp, Almelo, Netherlands
[8] Med Spectrum Twente, Enschede, Netherlands
[9] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1056/NEJMoa021375
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Maintenance of sinus rhythm is the main therapeutic goal in patients with atrial fibrillation. However, recurrences of atrial fibrillation and side effects of antiarrhythmic drugs offset the benefits of sinus rhythm. We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation. Methods: We randomly assigned 522 patients who had persistent atrial fibrillation after a previous electrical cardioversion to receive treatment aimed at rate control or rhythm control. Patients in the rate-control group received oral anticoagulant drugs and rate-slowing medication. Patients in the rhythm-control group underwent serial cardioversions and received antiarrhythmic drugs and oral anticoagulant drugs. The end point was a composite of death from cardiovascular causes, heart failure, thromboembolic complications, bleeding, implantation of a pacemaker, and severe adverse effects of drugs. Results: After a mean (+/-SD) of 2.3+/-0.6 years, 39 percent of the 266 patients in the rhythm-control group had sinus rhythm, as compared with 10 percent of the 256 patients in the rate-control group. The primary end point occurred in 44 patients (17.2 percent) in the rate-control group and in 60 (22.6 percent) in the rhythm-control group. The 90 percent (two-sided) upper boundary of the absolute difference in the primary end point was 0.4 percent (the prespecified criterion for noninferiority was 10 percent or less). The distribution of the various components of the primary end point was similar in the rate-control and rhythm-control groups. Conclusions: Rate control is not inferior to rhythm control for the prevention of death and morbidity from cardiovascular causes and may be appropriate therapy in patients with a recurrence of persistent atrial fibrillation after electrical cardioversion.
引用
收藏
页码:1834 / 1840
页数:7
相关论文
共 18 条
[1]   PREDICTORS OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION .1. CLINICAL-FEATURES OF PATIENTS AT RISK [J].
ANDERSON, DC ;
ASINGER, RW ;
NEWBURG, SM ;
FARMER, CC ;
WANG, K ;
BUNDLIE, SR ;
KOLLER, RL ;
JAGIELLA, WM ;
KREHER, S ;
JORGENSEN, CR ;
SHARKEY, SW ;
FLAKER, GC ;
WEBEL, R ;
NOLTE, B ;
STEVENSON, P ;
BYER, J ;
WRIGHT, W ;
CHESEBRO, JH ;
WIEBERS, DO ;
HOLLAND, AE ;
MILLER, DM ;
BARDSLEY, WT ;
LITIN, SC ;
MEISSNER, I ;
ZERBE, DM ;
MCANULTY, JH ;
MARCHANT, C ;
COULL, BM ;
FELDMAN, G ;
HAYWARD, A ;
GANDARA, E ;
MACMILLAN, K ;
BLANK, N ;
LEONARD, AD ;
KANTER, MC ;
ISENSEE, LM ;
QUIROGA, ES ;
PRESTI, CH ;
TEGELER, CH ;
LOGAN, WR ;
HAMILTON, WP ;
GREEN, BJ ;
BACON, RS ;
REDD, RM ;
CADELL, DJ ;
GOMEZ, CR ;
JANOSIK, DL ;
LABOVITZ, AJ ;
KELLEY, RE ;
CHAHINE, R .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) :1-5
[2]  
ANDERSON DC, 1992, ANN INTERN MED, V116, P6
[3]  
[Anonymous], 2001, CIRCULATION, V104, P2118
[4]  
COPLEN SE, 1991, CIRCULATION, V83, P714
[5]   EFFICACY AND SAFETY OF QUINIDINE THERAPY FOR MAINTENANCE OF SINUS RHYTHM AFTER CARDIOVERSION - A METAANALYSIS OF RANDOMIZED CONTROL TRIALS [J].
COPLEN, SE ;
ANTMAN, EM ;
BERLIN, JA ;
HEWITT, P ;
CHALMERS, TC .
CIRCULATION, 1990, 82 (04) :1106-1116
[6]   Medical progress: Atrial fibrillation. [J].
Falk, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1067-1078
[7]   Classification of atrial fibrillation [J].
Gallagher, MM ;
Camm, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (8A) :18N-27N
[8]   LEFT-VENTRICULAR DYSFUNCTION DUE TO ATRIAL-FIBRILLATION IN PATIENTS INITIALLY BELIEVED TO HAVE IDIOPATHIC DILATED CARDIOMYOPATHY [J].
GROGAN, M ;
SMITH, HC ;
GERSH, BJ ;
WOOD, DL .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (19) :1570-1573
[9]   Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation - Analysis of 2012 participants in the SPAF I-III clinical trials [J].
Hart, RG ;
Pearce, LA ;
McBride, R ;
Rothbart, RM ;
Asinger, RW .
STROKE, 1999, 30 (06) :1223-1229
[10]   Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention [J].
Hart, RG ;
Halperin, JL .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (09) :688-695